We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-0.1%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$2.83B
AUM Growth
-$798M
Cap. Flow
-$482M
Cap. Flow %
-17.04%
Top 10 Hldgs %
54.55%
Holding
115
New
16
Increased
15
Reduced
28
Closed
28

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$101M
2
BBNX
Beta Bionics
BBNX
+$29.7M
3
INSM icon
Insmed
INSM
+$27.9M
4
DYN icon
Dyne Therapeutics
DYN
+$25.3M
5
SLDB icon
Solid Biosciences
SLDB
+$21.4M

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$80.9M
2
NUVL
Nuvalent
NUVL
+$77.1M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$62.8M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$62.6M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$54.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSX icon
76
Biodesix
BDSX
$211M
$1.36M 0.05%
108,694
– –
SCPH
77
DELISTED
scPharmaceuticals
SCPH
$1.31M 0.05%
500,000
– –
TRAW icon
78
Traws Pharma
TRAW
$7.34M
$970K 0.03%
421,781
+257,624
+157% +$1.34M
RCKT icon
79
Rocket Pharmaceuticals
RCKT
$343M
$939K 0.03%
140,726
-237,858
-63% -$2.35M
CGEM icon
80
Cullinan Oncology
CGEM
$1.06B
$606K 0.02%
+80,100
New +$769K
LXEO icon
81
Lexeo Therapeutics
LXEO
$338M
$485K 0.02%
139,835
– –
APLT
82
DELISTED
Applied Therapeutics
APLT
$420K 0.01%
860,000
– –
NBTX
83
Nanobiotix
NBTX
$1.92B
$376K 0.01%
105,053
-161,040
-61% -$556K
ENSC icon
84
Ensysce Biosciences
ENSC
$3.88M
$222K 0.01%
86,666
– –
APYX icon
85
Apyx Medical
APYX
$162M
$206K 0.01%
150,000
– –
RVMDW icon
86
Revolution Medicines Inc Warrant
RVMDW
$95.7M
$9.5K ﹤0.01%
250,000
– –
SRZNW icon
87
Surrozen Inc Warrant
SRZNW
$36.6K
$5K ﹤0.01%
166,666
– –
ARVN icon
88
Arvinas
ARVN
$530M
– –
-740,749
Closed -$14.2M
BCYC
89
Bicycle Therapeutics
BCYC
$269M
– –
-197,108
Closed -$2.76M
CATX icon
90
Perspective Therapeutics
CATX
$327M
– –
-1,190,263
Closed -$3.8M
CGON icon
91
CG Oncology
CGON
$6.1B
– –
-419,450
Closed -$12M
CRNX icon
92
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-184,525
Closed -$9.43M
EW icon
93
Edwards Lifesciences
EW
$49.4B
– –
-145,000
Closed -$10.7M
FBRX icon
94
Forte Biosciences
FBRX
$1.57B
– –
-95,742
Closed -$2.17M
FULC icon
95
Fulcrum Therapeutics
FULC
$241M
– –
-238,000
Closed -$1.12M
IBRX icon
96
ImmunityBio
IBRX
$7.15B
– –
-1,221,734
Closed -$3.13M
IRTC icon
97
iRhythm Holdings
IRTC
$4.02B
– –
-65,153
Closed -$5.87M
LCTX icon
98
Lineage Cell Therapeutics
LCTX
$264M
– –
-7,236,843
Closed -$3.64M
NTRA icon
99
Natera
NTRA
$36.4B
– –
-125,000
Closed -$19.8M
NVAX icon
100
PUT
Novavax
NVAX
$1.21B
– –
-100,000
Closed -$804K
1 2 3
4
5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Perceptive Advisors held 115 positions worth $2.83B, down 22% from $3.63B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Perceptive Advisors withdrew a net $482M in Q1 2025, closing 28 positions and reducing 28 holdings. Its most notable exit was Procept Biorobotics, an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Beta Bionics worth $19.5M.

  • Perceptive Advisors's largest Q1 2025 buy was Beta Bionics: 1,593,608 shares worth $19.5M.
  • Perceptive Advisors added most to Edgewise Therapeutics in Q1 2025, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2025 reduction was Vaxcyte, cutting an estimated $80.9M.
  • Perceptive Advisors fully exited Procept Biorobotics in Q1 2025, selling an estimated $23.4M.
  • Perceptive Advisors's ten largest holdings make up 55% of its $2.83B portfolio in Q1 2025.
  • Perceptive Advisors opened 16 new positions and closed 28 in Q1 2025.
  • Perceptive Advisors's portfolio value fell 22% quarter-over-quarter to $2.83B.

Based on Perceptive Advisors's 13F filing for Q1 2025, filed 15 May 2025.